Literature DB >> 12053838

Hepatorenal syndrome. Definition, pathophysiology, and intervention.

Andrew E Briglia1, Frank A Anania.   

Abstract

Hepatorenal syndrome is a well characterized entity in which vasodilation of splanchnic vessels and intense constriction of the renal cortical vasculature occur in concert. The condition is often fatal unless orthotopic liver transplantation (OLT) is performed. Many extracorporeal blood purification techniques exist which can be offered to patients awaiting OLT. Continuous hemofiltration, with or without other modalities such as therapeutic plasma exchange and hemoperfusion, may be helpful in improving the level of consciousness of these patients. Unfortunately, mortality and hepatic regeneration do not appear to be affected by such interventions. The development of a hybrid bioartifical liver support system and pharmacologic manipulation of the hemodynamic perturbations that occur in HRS provide particularly appealing prospects as a means of providing a bridge to liver transplantation in the future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12053838     DOI: 10.1016/s0749-0704(01)00003-3

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  3 in total

1.  The effect of kidney diseases on survival in liver transplant patients.

Authors:  Inci Süleymanlar; Vural Taner Yılmaz; Hüseyin Koçak; Ayhan Dinçkan; Alihan Gürkan; Fevzi Ersoy; Gültekin Süleymanlar
Journal:  Int Urol Nephrol       Date:  2010-08-05       Impact factor: 2.370

2.  Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.

Authors:  Kannan Sridharan; Gowri Sivaramakrishnan
Journal:  J Gen Intern Med       Date:  2017-09-18       Impact factor: 5.128

3.  Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia; Thomas B Ledue; Wendy Y Craig
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.